File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1016/j.eururo.2021.06.022
- Scopus: eid_2-s2.0-85110498046
- PMID: 34275660
- WOS: WOS:000696981000017
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: A Systematic Review and Meta-analysis of Adjuncts to Minimally Invasive Treatment of Urethral Stricture in Men
Title | A Systematic Review and Meta-analysis of Adjuncts to Minimally Invasive Treatment of Urethral Stricture in Men |
---|---|
Authors | |
Keywords | Adjuncts Brachytherapy Mitomycin C Steroid Triamcinolone Urethral dilatation Urethral stricture Urethrotomy |
Issue Date | 2021 |
Citation | European Urology, 2021, v. 80, n. 4, p. 467-479 How to Cite? |
Abstract | Context: Urethral stricture disease (USD) is initially managed with minimally invasive techniques such as urethrotomy and urethral dilatation. Minimally invasive techniques are associated with a high recurrence rate, especially in recurrent USD. Adjunctive measures, such as local drug injection, have been used in an attempt to reduce recurrence rates. Objective: To systematically review evidence for the efficacy and safety of adjuncts used alongside minimally invasive treatment of USD. Evidence acquisition: A systematic review of the literature published between 1990 and 2020 was conducted in accordance with the PRISMA checklist. Evidence synthesis: A total of 26 studies were included in the systematic review, from which 13 different adjuncts were identified, including intralesional injection (triamcinolone, n = 135; prednisolone, n = 58; mitomycin C, n = 142; steroid-mitomycin C-hyaluronidase, n = 103, triamcinolone-mitomycin C-N-acetyl cysteine, n = 50; platelet-rich plasma, n = 44), intraluminal instillation (mitomycin C, n = 20; hyaluronic acid and carboxymethylcellulose, n = 70; captopril, n = 37; 192-iridium brachytherapy, n = 10), application via a lubricated catheter (triamcinolone, n = 124), application via a coated balloon (paclitaxel, n = 106), and enteral application (tamoxifen, n = 30; deflazacort, n = 36). Overall, 13 randomised controlled trials were included in the meta-analysis. Use of any adjunct was associated with a lower rate of USD recurrence (odds ratio [OR] 0.37, 95% confidence interval [CI] 0.27–0.50; p < 0.001) compared to no adjunct use. Of all the adjuncts, mitomycin C was associated with the lowest rate of USD recurrence (intralesional injection: OR 0.23, 95% CI 0.11–0.48; p < 0.001; intraluminal injection: OR 0.11, 95% CI 0.02–0.61; p = 0.01). Urinary tract infection (2.9–14%), bleeding (8.8%), and extravasation (5.8%) were associated with steroid injection; pruritis of the urethra (61%) occurred after instillation of captopril; mild gynaecomastia (6.7%) and gastrointestinal side effects (6.7%) were associated with oral tamoxifen. Conclusions: Adjuncts to minimally invasive treatment of USD appear to lower the recurrence rate and are associated with a low adjunct-specific complication rate. However, the studies included were at high risk of bias. Mitomycin C is the adjunct supported by the highest level of evidence. Patient summary: We reviewed studies on additional therapies (called adjuncts) to minimally invasive treatments for narrowing of the urethra in men. Adjuncts such as mitomycin C injection result in a lower recurrence rate compared to no adjunct use. The use of adjuncts appeared to be safe and complications are uncommon; however, the studies were small and of low quality. |
Persistent Identifier | http://hdl.handle.net/10722/328811 |
ISSN | 2023 Impact Factor: 25.3 2023 SCImago Journal Rankings: 6.928 |
ISI Accession Number ID |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Pang, Karl H. | - |
dc.contributor.author | Chapple, Christopher R. | - |
dc.contributor.author | Chatters, Robin | - |
dc.contributor.author | Downey, Alison P. | - |
dc.contributor.author | Harding, Christopher K. | - |
dc.contributor.author | Hind, Daniel | - |
dc.contributor.author | Watkin, Nick | - |
dc.contributor.author | Osman, Nadir I. | - |
dc.date.accessioned | 2023-07-22T06:24:14Z | - |
dc.date.available | 2023-07-22T06:24:14Z | - |
dc.date.issued | 2021 | - |
dc.identifier.citation | European Urology, 2021, v. 80, n. 4, p. 467-479 | - |
dc.identifier.issn | 0302-2838 | - |
dc.identifier.uri | http://hdl.handle.net/10722/328811 | - |
dc.description.abstract | Context: Urethral stricture disease (USD) is initially managed with minimally invasive techniques such as urethrotomy and urethral dilatation. Minimally invasive techniques are associated with a high recurrence rate, especially in recurrent USD. Adjunctive measures, such as local drug injection, have been used in an attempt to reduce recurrence rates. Objective: To systematically review evidence for the efficacy and safety of adjuncts used alongside minimally invasive treatment of USD. Evidence acquisition: A systematic review of the literature published between 1990 and 2020 was conducted in accordance with the PRISMA checklist. Evidence synthesis: A total of 26 studies were included in the systematic review, from which 13 different adjuncts were identified, including intralesional injection (triamcinolone, n = 135; prednisolone, n = 58; mitomycin C, n = 142; steroid-mitomycin C-hyaluronidase, n = 103, triamcinolone-mitomycin C-N-acetyl cysteine, n = 50; platelet-rich plasma, n = 44), intraluminal instillation (mitomycin C, n = 20; hyaluronic acid and carboxymethylcellulose, n = 70; captopril, n = 37; 192-iridium brachytherapy, n = 10), application via a lubricated catheter (triamcinolone, n = 124), application via a coated balloon (paclitaxel, n = 106), and enteral application (tamoxifen, n = 30; deflazacort, n = 36). Overall, 13 randomised controlled trials were included in the meta-analysis. Use of any adjunct was associated with a lower rate of USD recurrence (odds ratio [OR] 0.37, 95% confidence interval [CI] 0.27–0.50; p < 0.001) compared to no adjunct use. Of all the adjuncts, mitomycin C was associated with the lowest rate of USD recurrence (intralesional injection: OR 0.23, 95% CI 0.11–0.48; p < 0.001; intraluminal injection: OR 0.11, 95% CI 0.02–0.61; p = 0.01). Urinary tract infection (2.9–14%), bleeding (8.8%), and extravasation (5.8%) were associated with steroid injection; pruritis of the urethra (61%) occurred after instillation of captopril; mild gynaecomastia (6.7%) and gastrointestinal side effects (6.7%) were associated with oral tamoxifen. Conclusions: Adjuncts to minimally invasive treatment of USD appear to lower the recurrence rate and are associated with a low adjunct-specific complication rate. However, the studies included were at high risk of bias. Mitomycin C is the adjunct supported by the highest level of evidence. Patient summary: We reviewed studies on additional therapies (called adjuncts) to minimally invasive treatments for narrowing of the urethra in men. Adjuncts such as mitomycin C injection result in a lower recurrence rate compared to no adjunct use. The use of adjuncts appeared to be safe and complications are uncommon; however, the studies were small and of low quality. | - |
dc.language | eng | - |
dc.relation.ispartof | European Urology | - |
dc.subject | Adjuncts | - |
dc.subject | Brachytherapy | - |
dc.subject | Mitomycin C | - |
dc.subject | Steroid | - |
dc.subject | Triamcinolone | - |
dc.subject | Urethral dilatation | - |
dc.subject | Urethral stricture | - |
dc.subject | Urethrotomy | - |
dc.title | A Systematic Review and Meta-analysis of Adjuncts to Minimally Invasive Treatment of Urethral Stricture in Men | - |
dc.type | Article | - |
dc.description.nature | link_to_subscribed_fulltext | - |
dc.identifier.doi | 10.1016/j.eururo.2021.06.022 | - |
dc.identifier.pmid | 34275660 | - |
dc.identifier.scopus | eid_2-s2.0-85110498046 | - |
dc.identifier.volume | 80 | - |
dc.identifier.issue | 4 | - |
dc.identifier.spage | 467 | - |
dc.identifier.epage | 479 | - |
dc.identifier.eissn | 1873-7560 | - |
dc.identifier.isi | WOS:000696981000017 | - |